Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib.
Shuhei TeranishiChihiro SugimotoSatoshi NagaokaHirokazu NagayamaWataru SegawaAtsushi MiyasakaShuntaro HiroYukihito KajitaChihiro MaedaNobuaki KobayashMasaki YamamotoMakoto KudoTakeshi KanekoPublished in: Thoracic cancer (2022)
Poor PS was associated with poor prognosis in patients with EGFR mutation-positive advanced NSCLC treated with osimertinib as first-line therapy.